Top Market Shifts Transforming the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Landscape: Key Insights

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Through 2025?
The market valuation for transthyretin amyloid cardiomyopathy (attr-cm) therapies has seen rapid expansion lately, projecting an increase from a base of $10.36 billion in 2024 up to $13.29 billion the following year, which corresponds to a substantial compound annual growth rate of 28.2%; this robust growth trajectory across the historical span is fueled by several factors, including the escalating incidence of transthyretin amyloid cardiomyopathy itself, a higher occurrence of transthyretin amyloidosis especially within the elderly demographic, heightened levels of understanding among both medical practitioners and the patient population, and general improvements in the accessibility and quality of healthcare provisions.

What's the Projected Size of the Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market by 2029?
Exponential expansion is projected for the market dealing with transthyretin amyloid cardiomyopathy (attr-cm) treatments over the upcoming years, with valuations reaching $text{35.5 billion}$ by $text{2029}$, spurred by a compound annual growth rate (CAGR) of $text{27.8%}$. This surge throughout the projection timeframe is fueled by several factors, including the escalating incidence of transthyretin amyloidosis, a greater rate of diagnosing neuropathic conditions, the growth in the elderly demographic stratum, heightened consumer need for specialized pharmaceuticals addressing the rare condition's symptoms, and an overall uplift in healthcare requirements. Key developments anticipated during this forecast window involve novel methods for detection, the creation of cutting-edge approaches for managing therapeutic interventions, the introduction of unique and precisely aimed therapies for transthyretin amyloidosis, progress in diagnostic methodologies, and improvements in cardiac magnetic resonance imaging (MRI) applications.

View the full report here:
https://www.thebusinessresearchcompany.com/report/transthyretin-amyloid-cardiomyopathy-attr-cm-treatment-global-market-report

Top Growth Drivers in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Industry: What's Accelerating the Market?
The escalating incidence of long-term illnesses, defined as conditions developing gradually over a year or longer demanding ongoing medical attention, is forecast to stimulate the expansion of the market for transthyretin amyloid cardiomyopathy (ATTR-CM) therapies. This increase in chronic ailments stems from several contributing elements, including the aging global demographic, decreased physical activity, poor dietary habits, growing rates of obesity, and exposure to environmental toxins. Treatments for transthyretin amyloid cardiomyopathy contribute to disease management for these related chronic conditions by stabilizing the transthyretin protein, thereby decreasing amyloid deposition, enhancing cardiac performance, and easing associated symptoms. To illustrate the scale, data from the World Health Organization, which is the United Nations' specialized agency situated in Switzerland, reported in September 2023 that annually, 41 million fatalities occur, with three-quarters of these being attributable to non-communicable diseases or chronic conditions; specifically, cardiovascular ailments accounted for 17.9 million deaths worldwide, cancer for 9.3 million, chronic respiratory diseases for 4.1 million, and diabetes for 2.0 million, consequently underscoring how the growing burden of chronic diseases fuels the demand within the ATTR-CM treatment sector.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21304&type=smp

What Trends Will Shape the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Through 2029 and Beyond?
Key players within the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment landscape are concentrating their efforts on pioneering novel therapeutic approaches for ATTR-CM, specifically pursuing orally administered prescription drugs designed either to affix to and thereby stabilize transthyretin (TTR) proteins or to decrease the accumulation of amyloid fibrils within cardiac tissue. Oral prescription drugs constitute pharmaceuticals directed by a clinician that are ingested, usually presented as pills, capsules, or liquid formulations. As an illustration, in November of 2024, the U.S. Food and Drug Administration sanctioned Attruby (acoramidis), developed by BridgeBio Pharma Inc., a biotechnology entity situated in the United States, for application in managing ATTR-CM in adult patients; this particular agent functions by stabilizing the TTR protein, resulting in a reduction of cardiac fatalities and admissions to hospitals, with clinical investigations demonstrating its favorable tolerability profile and the swift advantages it delivers by addressing the fundamental etiology of the ailment.

What Are the Main Segments in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
The transthyretin amyloid cardiomyopathy (attr-cm) treatmentmarket covered in this report is segmented -

1) By Type: Transthyretin Stabilizers; Nonsteroidal Anti-inflammatory Drugs (NSAID); RNAi Therapy; Other Types
2) By Indication: Wild type ATTR Amyloidosis; Hereditary ATTR amyloidosis
3) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End Users

Subsegments:
1) By Transthyretin Stabilizers: Tafamidis; Diflunisal
2) By Nonsteroidal Anti-inflammatory Drugs (NSAIDs): Aspirin; Ibuprofen; Other NSAIDs
3) By RNAi Therapy: Patisiran; Vutrisiran
4) By Other Types: Gene Silencing Therapies; Immunotherapy Approaches; Emerging Small Molecule Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21304&type=smp

Which Top Companies are Driving Growth in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market?
Major companies operating in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market are Pfizer Inc., Bayer AG., AstraZeneca Plc, GlaxoSmithKline Plc., Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., MedStar Health Inc, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals Inc., Akcea Therapeutics Inc, BridgeBio Pharma Inc., Prothena Corporation plc, Intellia Therapeutics Inc., Alexion Pharmaceuticals Inc., Neurimmune Holding AG, SOM Biotech S.L, Corino Therapeutics Inc, Eidos Therapeutics Inc, CRISPR Therapeutics AG

Which Regions Will Dominate the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Through 2029?
North America was the largest region in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the transthyretin amyloid cardiomyopathy (ATTR-CM) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21304

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.